Weinberg OK, Arber DA. Mixed-phenotype acute Leukemia: historical overview and a new definition. Leukemia. 2010;24(11):1844–51.
Khan M, Siddiqi R, Naqvi K. An update on classification, genetics, and clinical approach to mixed phenotype acute Leukemia (MPAL). Ann Hematol. 2018;97(6):945–53.
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–19.
George BS, Yohannan B, Gonzalez A, Rios A. Mixed-phenotype Acute Leukemia: clinical diagnosis and therapeutic strategies. Biomedicines. 2022;10(8):1974.
Mi X, Griffin G, Lee W, Patel S, Ohgami R, Ok CY, et al. Genomic and clinical characterization of B/T mixed phenotype acute Leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018;93(11):1358–67.
Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.
Lazzarotto D, Tanasi I, Vitale A, Piccini M, Dargenio M, Giglio F, et al. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute Leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a campus ALL study. Ann Hematol. 2023;102(5):1099–109.
Maruffi M, Sposto R, Oberley MJ, Kysh L, Orgel E. Therapy for children and adults with mixed phenotype acute Leukemia: a systematic review and meta-analysis. Leukemia. 2018;32(7):1515–28.
Polska Grupa ds. Leczenia Białaczek u Dorosłych. Protokół leczenia ostrej białaczki limfoblastycznej u dorosłych. Polish Adult Leukemia Group (PALG) guidelines for the treatment of ALL. [Internet]. 2022 [cited 2023 Jul 16]. Available from: www.palg.pl.
Rasekh EO, Osman R, Ibraheem D, Madney Y, Radwan E, Gameel A, et al. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute Leukemia: a comparative study between adults and pediatric MPAL patients. Ann Hematol. 2021;100(3):699–707.
Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic Leukemia. Blood. 2010;115(7):1351–3.
Béné MC, Porwit A. Mixed Phenotype/Lineage Leukemia: has anything changed for 2021 on diagnosis, classification, and treatment? Curr Oncol Rep. 2022;24(8):1015–22.
Hongo T, Okada S, Ohzeki T, Ohta H, Nishimura SI, Hamamoto K, et al. Low plasma levels of hemostatic proteins during the induction phase in children with acute lymphoblastic Leukemia: a retrospective study by the JACLS. Japan Association of Childhood Leukemia Study. Pediatr Int off J Jpn Pediatr Soc. 2002;44(3):293–9.
Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52(12):2237–53.
Riley DO, Schlefman JM, Vitzthum Von Eckstaedt VHC, Morris AL, Keng MK, El Chaer F. Pegaspargase in practice: minimizing toxicity, Maximizing Benefit. Curr Hematol Malig Rep. 2021;16(3):314–24.
Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related Thrombosis in paediatric and adult patients with acute lymphoblastic Leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152(4):452–9.
Payne JH, Vora AJ. Thrombosis and acute lymphoblastic Leukaemia. Br J Haematol. 2007;138(4):430–45.
De Stefano V, Sorà F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of Thrombosis in patients with acute Leukemia: occurrence of Thrombosis at diagnosis and during treatment. J Thromb Haemost JTH. 2005;3(9):1985–92.
Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, et al. Symptomatic venous thromboembolism in acute Leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res. 2005;115(1–2):59–64.
Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic Leukemia or lymphoblastic Lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica. 2008;93(10):1488–94.
Chen R, Atenafu EG, Seki J, Liu X, Chan S, Gupta V, et al. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: a retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic Leukaemia. Br J Haematol. 2023;201(4):645–52.
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C, et al. Acute lymphoblastic Leukaemia in adult patients: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol off J Eur Soc Med Oncol. 2016;27(suppl 5):v69–82.
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, et al. Incidence of venous Thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic Leukemia. Int J Hematol Oncol. 2020;9(3):IJH28.
Elliott MA, Wolf RC, Hook CC, Pruthi RK, Heit JA, Letendre LL, et al. Thromboembolism in adults with acute lymphoblastic Leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45(8):1545–9.
Gugliotta L, Mazzucconi MG, Leone G, Mattioli-Belmonte M, Defazio D, Annino L, et al. Incidence of thrombotic Complications in adult patients with acute lymphoblastic Leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group. Eur J Haematol. 1992;49(2):63–6.
Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic Leukemia. Eur J Haematol. 2016;96(4):375–80.
Tuckuviene R, Bjerg CL, Jonsson OG, Langstrom S, Rank CU, Ranta S, et al. Pulmonary Embolism in acute lymphoblastic Leukemia — an observational study of 1685 patients treated according to the NOPHO ALL2008 protocol. Res Pract Thromb Haemost. 2020;4(5):866–71.
Kuhle S, Spavor M, Massicotte P, Halton J, Cherrick I, Dix D, et al. Prevalence of post-thrombotic syndrome following asymptomatic Thrombosis in survivors of acute lymphoblastic Leukemia. J Thromb Haemost. 2008;6(4):589–94.
Silvis SM, de Sousa DA, Ferro JM, Coutinho JM. Cerebral venous Thrombosis. Nat Rev Neurol. 2017;13(9):555–65.
Kristoffersen ES, Harper CE, Vetvik KG, Zarnovicky S, Hansen JM, Faiz KW. Incidence and mortality of cerebral venous Thrombosis in a Norwegian Population. Stroke. 2020;51(10):3023–9.
Couturier MA, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, et al. Cerebral venous Thrombosis in adult patients with acute lymphoblastic Leukemia or lymphoblastic Lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90(11):986–91.
Dentali F, Gianni M, Crowther MA, Ageno W. Natural history of cerebral vein Thrombosis: a systematic review. Blood. 2006;108(4):1129–34.
Coutinho JM, Zuurbier SM, Stam J. Declining mortality in cerebral venous Thrombosis: a systematic review. Stroke. 2014;45(5):1338–41.
Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, Investigators ISCVT. Prognosis of cerebral vein and dural sinus Thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35(3):664–70.
Zuurbier SM, Lauw MN, Coutinho JM, Majoie CBLM, van der Holt B, Cornelissen JJ, et al. Clinical course of cerebral venous Thrombosis in adult Acute Lymphoblastic Leukemia. J Stroke Cerebrovasc Dis off J Natl Stroke Assoc. 2015;24(7):1679–84.
Wani NA, Kosar T, Pala NA, Qureshi UA. Sagittal sinus Thrombosis due to L-asparaginase. J Pediatr Neurosci. 2010;5(1):32–5.
van der Sluis IM, Vrooman LM, Pieters R, Baruchel A, Escherich G, Goulden N, et al. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016;101(3):279–85.
Skipper MT, Rank CU, Jarvis KB, Lynggaard LS, Andrés-Jensen L, Quist-Paulsen P, et al. Cerebral sinovenous Thrombosis and asparaginase re-exposure in patients aged 1–45 years with acute lymphoblastic Leukaemia: a NOPHO ALL2008 study. EJHaem. 2022;3(3):754–63.
Zwicker JI, Wang TF, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost JTH. 2020;18(2):278–84.
Napolitano M, Saccullo G, Marietta M, Carpenedo M, Castaman G, Cerchiara E, et al. Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfus Trasfus Sangue. 2019;17(3):171–80.
Durrani J, Malik F, Ali N, Jafri SIM. To be or not to be a case of heparin resistance. J Community Hosp Intern Med Perspect. 2018;8(3):145–8.
Polska Grupa ds. Leczenia Białaczek u Dorosłych. Protokół leczenia ostrej białaczki limfoblastycznej u dorosłych. Polish Adult Leukemia Group (PALG) guidelines for the treatment of ALL. [Internet]. 2018 [cited 2023 Jul 16]. Available from: www.palg.pl.
Anderson DR, Stock W, Karrison TG, Leader A. D-dimer and risk for Thrombosis in adults with newly diagnosed acute lymphoblastic Leukemia. Blood Adv. 2022;6(17):5146–51.
Add Comment